VTGN
VistaGen Therapeutics, Inc. NASDAQ Listed Jun 21, 2011$0.25
+2.43%
vs $0.24
Mkt Cap $7.6M
52w Low $0.23
0.5% of range
52w High $4.90
50d MA $0.59
200d MA $1.71
P/E (TTM)
-0.1x
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.0x
ROE
-110.4%
P/FCF
-0.2x
RSI (14)
33.10
ATR (14)
$0.07
Beta
0.33
50d MA
$0.59
200d MA
$1.71
Avg Volume
3.0M
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
343 Allerton Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | AMC | -0.42 | -0.37 | +11.9% | 0.57 | +1.2% | +20.4% | +0.0% | -2.9% | -4.5% | -1.2% | — |
| Feb 12, 2026 | AMC | -0.51 | -0.45 | +11.8% | 0.55 | -11.9% | -7.2% | +4.8% | -2.7% | +14.9% | -5.6% | — |
| Nov 13, 2025 | AMC | -0.51 | -0.54 | -5.9% | 3.80 | -2.1% | +0.0% | +16.3% | +4.8% | -2.8% | -1.1% | — |
| Aug 7, 2025 | AMC | -0.47 | -0.47 | +0.0% | 2.73 | +1.5% | +8.8% | -4.4% | +0.7% | +2.4% | +1.0% | — |
| Jun 17, 2025 | AMC | -0.52 | -0.43 | +17.3% | 2.38 | -2.5% | -13.4% | -2.9% | -2.0% | +6.6% | -2.9% | — |
| Feb 13, 2025 | AMC | -0.48 | -0.46 | +4.2% | 2.85 | +3.5% | +4.2% | -1.0% | -3.1% | +0.7% | +2.1% | — |
| Nov 7, 2024 | AMC | -0.40 | -0.42 | -5.0% | 3.12 | +0.3% | +0.6% | -3.8% | -3.0% | -3.8% | -3.2% | — |
| Aug 13, 2024 | AMC | -0.41 | -0.35 | +14.6% | 3.39 | -5.6% | -3.2% | +3.0% | -3.0% | +5.8% | +3.5% | — |
| Jun 11, 2024 | AMC | -0.34 | -0.25 | +26.5% | 3.77 | +0.8% | -2.1% | -4.6% | +0.0% | -2.8% | -3.2% | — |
| Feb 13, 2024 | AMC | -0.31 | -0.22 | +29.0% | 4.90 | +3.9% | +10.0% | +0.6% | -5.9% | -2.0% | -3.6% | — |
| Nov 9, 2023 | AMC | -0.68 | -0.66 | +2.9% | 2.89 | -0.3% | -11.1% | +6.2% | +16.5% | +3.5% | +0.9% | — |
| Aug 10, 2023 | AMC | -0.86 | -0.94 | -9.3% | 7.52 | -7.0% | -14.6% | +8.4% | -9.8% | -9.9% | -2.1% | — |
| Jun 22, 2023 | AMC | -1.50 | -1.75 | -16.7% | 1.75 | +0.0% | -2.3% | -0.6% | -0.6% | +1.8% | +4.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17 | Jefferies | Downgrade | Buy → Hold | — | $4.36 | $0.88 | -79.8% | -80.3% | -14.1% | +5.1% | -3.8% | -4.7% |
| Dec 17 | Maxim Group | Downgrade | Buy → Hold | — | $4.36 | $0.88 | -79.8% | -80.3% | -14.1% | +5.1% | -3.8% | -4.7% |
| Dec 17 | William Blair | Downgrade | Outperform → Market Perform | — | $4.36 | $0.88 | -79.8% | -80.3% | -14.1% | +5.1% | -3.8% | -4.7% |
| Dec 7 | Jefferies | Upgrade | Hold → Buy | — | $4.43 | $4.84 | +9.3% | +9.9% | -4.5% | -7.1% | +1.2% | +8.7% |
| Sep 5 | Maxim Group | Maintains | Buy → Buy | — | $5.92 | $6.14 | +3.7% | +4.9% | +5.0% | +0.9% | +2.4% | -1.3% |
| Aug 7 | Maxim Group | Upgrade | Hold → Buy | — | $1.68 | $21.60 | +1185.7% | +676.8% | -43.1% | -5.1% | +6.8% | -14.6% |
| Jul 26 | Maxim Group | Downgrade | Buy → Hold | — | $5.40 | $5.10 | -5.6% | -11.1% | +0.0% | -6.2% | -6.7% | +0.0% |
| Jul 22 | William Blair | Downgrade | Outperform → Market Perform | — | $32.10 | $6.30 | -80.4% | -86.0% | +20.0% | -11.1% | +0.0% | -6.3% |
| May 20 | Baird | Maintains | Outperform → Outperform | — | $69.00 | $78.90 | +14.3% | +12.2% | +9.3% | +5.7% | -0.3% | -11.4% |
| Feb 18 | Jefferies | Maintains | Buy → Buy | — | $61.80 | $70.80 | +14.6% | +20.4% | +19.4% | -13.9% | -2.4% | -5.2% |
| Jan 4 | William Blair | Upgrade | Market Perform → Outperform | — | $58.20 | $64.50 | +10.8% | +18.0% | -10.5% | +2.0% | +8.1% | -4.0% |
| Oct 8 | Aegis Capital | Maintains | Buy → Buy | — | $21.00 | $21.30 | +1.4% | +5.7% | +1.4% | +0.0% | +6.7% | -5.0% |
| Aug 28 | William Blair | Maintains | Outperform → Outperform | — | $19.20 | $21.90 | +14.1% | +4.7% | +1.5% | +0.0% | +2.9% | +12.9% |
| Jul 22 | Chardan Capital | Downgrade | Buy → Neutral | — | $18.60 | $18.60 | +0.0% | -9.7% | +7.1% | -11.7% | -1.9% | -1.9% |
| Jun 27 | Maxim Group | Maintains | Buy → Buy | — | $40.50 | $45.00 | +11.1% | +0.0% | -1.5% | +3.0% | +2.9% | -0.7% |
| May 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.70 | $30.00 | +1.0% | -2.0% | +51.5% | -10.2% | +5.3% | +1.4% |
No insider trades available.
8-K · 8.01
!! High
VistaGen Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 30
8-K · 5.02
!!! Very High
VistaGen Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 17
8-K · 2.02
!! High
VistaGen Therapeutics, Inc. -- 8-K 2.02: Earnings Results
VistaGen Therapeutics reported earnings results via press release filing, though specific financial metrics and performance details require review of the attached exhibit for investor assessment.
Jun 15
8-K · 8.01
!! High
VistaGen Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
I cannot provide specific analysis without the actual press release content. Please share the press release text or key details from Exhibit 99.1 to determine the material event and its investor implications.
Jun 9
8-K · 8.01
!! High
VistaGen Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 12
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Without specific details about the executive change at VTGN, investors cannot assess whether this leadership transition strengthens or weakens the company's direction and financial prospects.
Apr 13
8-K
Unknown — 8-K Filing
VTGN risks Nasdaq delisting if it fails to restore board independence compliance within the cure period, which would severely damage liquidity and institutional investor participation.
Apr 2
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
VTGN's executive change filing lacks specificity about who departed or joined, limiting investors' ability to assess leadership continuity risks or strategic direction shifts.
Mar 18
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate disclosure suggests VTGN made a presentation or announcement via Reg FD, but provides no material information, so investors should seek the actual presentation content to assess any stock impact.
Mar 16
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
VTGN disclosed sufficient cash reserves to fund operations through 2027, reducing near-term liquidity risk and providing runway for social anxiety disorder treatment development without immediate financing needs.
Mar 11
8-K · 5.02
!!! Very High
Vistagen Therapeutics, Inc. -- 8-K 5.02: Executive Change
Vistagen Therapeutics experienced executive turnover as director Paul Edick resigned, potentially signaling internal changes but lacking material operational impact details.
Feb 20
8-K
Vistagen Therapeutics, Inc. -- 8-K Filing
Vistagen's Phase 3 PALISADE-4 trial for fasedienol in social anxiety disorder remains on track with topline results anticipated in H1 2026, supporting potential near-term catalysts for the clinical-stage biotech.
Feb 12
8-K
Vistagen Therapeutics, Inc. -- 8-K Filing
Vistagen Therapeutics faces potential delisting from Nasdaq due to minimum bid price non-compliance, with uncertain prospects for regaining compliance within the 180-day cure period.
Feb 6
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF | 277,110 | $158K | Mar 2026 |
| 2 | Guggenheim Active Allocation Fund | 38 | $22 | Feb 2026 |
Valuation
Market Cap
$7.6M
Enterprise Value
-$72.8M
P/E (TTM)
-0.13x
Forward P/E
—
PEG Ratio
-0.15x
P/B
0.11x
P/S
6.02x
P/FCF
-0.18x
EV/EBITDA
—
Shares Out
30.7M
Financials (TTM)
Revenue
$1.3M
Net Income
-$69.7M
EBITDA
-$69.4M
Free Cash Flow
-$42.3M
Op Cash Flow
-$42.1M
EPS Basic
$-1.67
EPS Diluted
$-1.87
EPS Forward
$-1.10
Gross Margin
71.8%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$84.3M
Total Liab.
$14.0M
Total Equity
$70.4M
Cash
$80.5M
LT Debt
$0
Book Value/Sh
$2.29
Debt/Equity
0.02x
Current Ratio
6.51
Quick Ratio
6.51
Returns & Growth
ROE
-110.4%
ROA
-86.4%
ROIC
-77.4%
Rev Growth YoY
-54.3%
EPS Growth YoY
-9.9%
Price Returns
2W
-63.9%
1M
-55.6%
3M
-54.1%
6M
-63.3%
12M
-87.6%
Technicals
52W High
$4.90
52W Low
$0.23
50d MA
$0.59
200d MA
$1.71
RSI (14)
33.10
ATR (14)
$0.07
Beta
0.33
Avg Volume
3.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$0.95
High
$1.00
Low
$0.90
Median
$0.95
Data updated apr 27, 2026 8:23am
· Source: financialmodelingprep.com